Trial start 1: A Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001 source ↗
Raise Private equity round — Series A: $65M (total, as published), announced May 8, 2025. Source: company's own press page. source ↗
Upcoming milestones
2027-03 (ESTIMATED) · 1 · A Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001 · NCT07867288
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $65.0M. Last 2 years.
Private equity round — Series A: $65M (total, as published), announced May 8, 2025. Source: company's own press page. source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
